<DOC>
	<DOCNO>NCT00791830</DOCNO>
	<brief_summary>Angiotensin II receptor blocker ( ARB ) know preserve kidney function among patient kidney disease reduce renal function , among haemodialysis patient . Haemodialysis patient often lose residual renal function initiate dialysis lead worsen quality life , increased morbidity mortality . In study ARB investigate double blind , randomise , parallel group , placebo control manner see , ARB save residual renal function among haemodialysis patient . Potential cardiovascular benefit treatment also address .</brief_summary>
	<brief_title>Saving Residual Renal Function Among Haemodialysis Patients Receiving Irbesartan</brief_title>
	<detailed_description>Haemodialysis patient often lose residual renal function rather quickly initiation dialysis - average loss 30 % per year . Loss residual kidney function lead deteriorate quality life , morbidity high mortality . Many cause identify , one - knowledge - address save residual renal function among haemodialysis patient far . Hypothesis : Irbesartan reduce loss residual kidney function among haemodialysis patient leave ventricular hypertrophy arterial stiffness less pronounce 1 year treatment . Methods : 80 patient randomise receive either irbesartan , angiotensin II receptor blocker ( ARB ) , placebo 1 year . Residual renal function estimate one-two week initiate project medicine , order estimate acute effect ARB residual renal function study population . Thereafter , glomerular filtration rate ( GFR ) urine volume determine 3 , 6 , 9 12 month give regression line patient . 8 dialysis unit recruit patient . Investigations : - creatinine-urea-clearance 24h urine collection - applanation tonometry - cardiac output - echocardiography - QoL questionnaire - endocrinological cardiovascular marker blood urine Perspectives : It well-known ceased urine production tremendous negative effect quality life haemodialysis patient . Lately show residual renal function great impact dialysis dose morbidity well mortality . Among peritoneal dialysis patient Asia angiotensin-converting enzyme inhibitor ( ACEI ) ARB save residual renal function , preservation renal function address haemodialysis patient , ACEI ARB prescribe roughly 15 % . If study confirm hypothesis grow population haemodialysis patient offer irbesartan .</detailed_description>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Irbesartan</mesh_term>
	<mesh_term>Angiotensin II Type 1 Receptor Blockers</mesh_term>
	<criteria>Haemodialysis patient Haemodialysis treatment maximum 12 month &gt; 18 year old informed consent urine volume &gt; 300 ml / 24 hour contraception fertile woman Systolic blood pressure &lt; 110 mm Hg Able comprehend aim project follow instruction Allergy irbesartan/ACEinhibitors/ARBs Myocardial infarction unstable angina pectoris last 3 month Ejection fraction &lt; 30 % Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Residual renal function</keyword>
	<keyword>Haemodialysis</keyword>
	<keyword>Applanation tonometry</keyword>
	<keyword>Cardiac output</keyword>
	<keyword>Quality life</keyword>
	<keyword>Angiotensin II Type 1 Receptor Blockers</keyword>
</DOC>